{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:31:06Z","timestamp":1788690666884,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA006927\u201056"],"award-info":[{"award-number":["P30CA006927\u201056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046592"],"award-info":[{"award-number":["P30CA046592"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007322","name":"Fox Chase Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010174","name":"University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiosarcomas are rare mesenchymal sarcomas that can present as primary cutaneous or noncutaneous disease. They express a variety of vascular endothelial growth factor receptors. The authors hypothesized that the treatment of angiosarcoma with pazopanib, a multikinase inhibitor with activity against vascular endothelial growth factor receptors, would result in disease response and prolonged disease stabilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an open\u2010label, phase 2 trial of pazopanib in patients who had incurable angiosarcoma. The co\u2010primary end points were response according to the Response Evaluation Criteria in Solid Tumors and progression\u2010free survival (PFS) at 3\u2009months. The starting dose of pazopanib was 800\u2009mg daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty\u2010nine patients were accrued between 2011 and 2018, and 22 patients were evaluable for response. Toxicities were similar to those identified in prior reports. There was one partial response (3%), and the clinical benefit rate (including complete responses, partial responses, and stable disease) was 48%, which was observed more frequently in patients who had cutaneous disease. The median PFS was 14.4\u2009weeks, and the 3\u2010month PFS rate determined by Kaplan\u2013Meier estimate was 54.6% (95% CI, 36.0%\u201382.9%), meeting the primary study objective. The Kaplan\u2013Meier overall survival estimate was 16.1\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pazopanib therapy in patients who had incurable angiosarcoma was associated with meaningful disease control, especially in those who had cutaneous disease with limited objective responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lay Summary<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Angiosarcoma is a rare cancer that can be found on the skin or in internal organs.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This study tested pazopanib, an oral targeted medication, to determine its benefit in patients with angiosarcoma who could not undergo the removal of their tumors by surgery.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Pazopanib treatment was safe, and no new side effects were reported.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The study showed that pazopanib controlled tumor growth in one half of patients at 3\u2009months and was more common in angiosarcomas of the skin; it led to tumor shrinkage in a minority of patients (1 of 29).<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.34403","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T03:01:29Z","timestamp":1660014089000},"page":"3516-3522","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["<scp>OER\u2010073:<\/scp>\n                    A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma"],"prefix":"10.1002","volume":"128","author":[{"given":"Julio Alvarenga","family":"Thiebaud","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology Fox Chase Cancer Center  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6080-9336","authenticated-orcid":false,"given":"Vinod","family":"Ravi","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Litwin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Fox Chase Cancer Center  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-4163","authenticated-orcid":false,"given":"Scott M.","family":"Schuetze","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujana","family":"Movva","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Fox Chase Cancer Center  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Agulnik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-4845","authenticated-orcid":false,"given":"Andrew S.","family":"Kraft","sequence":"additional","affiliation":[{"name":"Univeristy of Arizona Cancer Center  Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8855-327X","authenticated-orcid":false,"given":"Eric D.","family":"Tetzlaff","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Fox Chase Cancer Center  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-7732","authenticated-orcid":false,"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-890X","authenticated-orcid":false,"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Fox Chase Cancer Center  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-015-0028-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70023-1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm381"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200505000-00011"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-5004-7"},{"key":"e_1_2_9_9_1","unstructured":"National Comprehensive Cancer Network (NCCN). Soft Tissue Sarcoma NCCN;2019.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00050-8"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1276"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1269"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8505"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.3146"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2068"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20827"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.111770"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4495"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds237"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764"},{"issue":"9829","key":"e_1_2_9_21_1","first-page":"879","article-title":"Pazopanib for metastatic soft\u2010tissue sarcoma (Palette): a randomised, double\u2010blind, placebo\u2010controlled phase 3 trial","volume":"379","author":"Graaf WT","year":"2012","journal-title":"Lancet"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy299.047"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.01.006"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1234068"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-016-0831-z"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13558"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0749-z"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139080"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194816"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002990"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001561"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.34403","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:44:20Z","timestamp":1760262260000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":30,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/cncr.34403"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34403","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742273058.793595228","asserted-by":"object"}]},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"2022-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}